JLINX launched amid excitement at pharma's role in stimulating biotech discoveries

23 April 2016

A new initiative launched to harness some of Europe’s most exciting biotech prospects could help to inspire the next generation of drug discoveries, according to bosses at US pharma giant Johnson & Johnson (NYSE: JNJ) and its subsidiary Janssen.

They officially launched Johnson & Johnson Innovation, JLINX, at the newly-modernized Janssen Campus in Belgium this week.

The arrangement does not just offer researchers the chance to use Janssen’s laboratories and all their testing facilities and other infrastructure, as well as to make use of its scientific expertise – both vital in reducing the cost and time of carrying out research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK